PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-3.66%
Negative net income growth while Biotechnology median is 1.37%. Seth Klarman would suspect a firm-specific problem if peers maintain profit growth.
13.04%
D&A growth of 13.04% while Biotechnology median is zero at 0.00%. Walter Schloss would question intangible or new expansions driving that cost difference.
100.00%
Deferred tax growth of 100.00% while Biotechnology median is zero at 0.00%. Walter Schloss would see a difference that might matter for future cash flow if significant.
1.43%
SBC growth of 1.43% while Biotechnology median is zero at 0.00%. Walter Schloss would question expansions or staff additions causing more equity grants.
-401.62%
Working capital is shrinking yoy while Biotechnology median is -64.62%. Seth Klarman would see an advantage if sales remain robust.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
AP shrinks yoy while Biotechnology median is 0.00%. Seth Klarman would see better immediate cost coverage if top-line remains intact.
-97.99%
Other WC usage shrinks yoy while Biotechnology median is -12.56%. Seth Klarman would see an advantage if top-line is stable or growing.
-100.00%
Other non-cash items dropping yoy while Biotechnology median is -17.93%. Seth Klarman would see a short-term advantage if real fundamentals remain intact.
-93.84%
Negative CFO growth while Biotechnology median is -9.47%. Seth Klarman would suspect a firm-specific operational weakness if peers maintain growth.
-375.00%
CapEx declines yoy while Biotechnology median is 0.00%. Seth Klarman would note a short-term FCF advantage if revenue is stable.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-375.00%
Reduced investing yoy while Biotechnology median is 5.53%. Seth Klarman sees potential advantage in near-term liquidity if revenue remains stable.
No Data
No Data available this quarter, please select a different quarter.
-84.27%
We reduce issuance yoy while Biotechnology median is 0.00%. Seth Klarman might see an advantage in preserving per-share value unless expansions are neglected.
No Data
No Data available this quarter, please select a different quarter.